Iterum Therapeutics PLC (ITRM) Financials
$0.06
As on 02-Jun-2026 09:30EDT
Market cap
$2 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Cashflow ($ Mln) |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-26.77
|
-39.33
|
-18.47
|
-15.84
|
-54.53
|
|||||
|
Cash Flow from Investing Activities
|
--
|
18.21
|
23.34
|
13.96
|
-54.60
|
-0.01
|
|||||
|
Cash from Financing Activities
|
--
|
26.69
|
1.03
|
-1.82
|
83.13
|
64.48
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
9.94
|
Financials Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-0.84
|
-1.26
|
-2.91
|
-3.33
|
-6.93
|
-19.19
|
|||||
|
Cash EPS ($)
|
--
|
-1.24
|
-2.78
|
-3.20
|
-6.77
|
-19.13
|
|||||
|
Adjusted Book Value ($)
|
--
|
--
|
--
|
2.10
|
3.80
|
--
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
-1.36
|
-2.98
|
-1.39
|
-1.20
|
-20.12
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
-1.36
|
-2.99
|
-1.39
|
-1.20
|
-20.13
|
Profitability Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-91.75
|
-108.62
|
-64.04
|
-234.23
|
680.35
|
|||||
|
ROE (%)
|
--
|
472.61
|
-355.35
|
-113.59
|
56,347.08
|
135.44
|
|||||
|
ROA (%)
|
-73.30
|
-69.93
|
-82.44
|
-56.12
|
-147.33
|
-177.67
|
|||||
|
EBIT Margin (%)
|
-6,253.08
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Net Margin (%)
|
-6,913.08
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Profit Margin (%)
|
-0.01
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-85.11
|
--
|
--
|
--
|
--
|
-1.00
|
|||||
|
EBIT Growth (%)
|
13.35
|
39.41
|
13.03
|
51.03
|
-135.87
|
64.48
|
|||||
|
Net Profit Growth (%)
|
11.76
|
35.44
|
13.64
|
51.47
|
-76.06
|
49.57
|
|||||
|
EPS Growth (%)
|
58.25
|
0.57
|
0.13
|
0.52
|
0.64
|
0.82
|
|||||
|
Book Value Growth (%)
|
71.93
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
-1.41
|
-0.68
|
-0.25
|
-0.06
|
-0.05
|
|||||
|
Price / Book Value
|
0.43
|
-8.54
|
-4.06
|
0.40
|
0.10
|
-0.05
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
0.55
|
-2.59
|
-0.61
|
0.49
|
0.55
|
-0.94
|
|||||
|
Close Price ($)
|
0.67
|
1.77
|
1.97
|
0.84
|
5.88
|
14.84
|
|||||
|
High Price ($)
|
3.02
|
3.02
|
2.50
|
7.05
|
44.93
|
90.30
|
|||||
|
Low Price ($)
|
0.61
|
0.81
|
0.62
|
0.60
|
5.86
|
6.77
|
|||||
|
Market Cap ($ Cr)
|
1.60
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
-4.53
|
-11.16
|
-2.96
|
1.08
|
0.61
|
-0.95
|
|||||
|
Short term debt to equity ratio
|
-0.04
|
-3.54
|
-0.06
|
0.01
|
0.04
|
-0.14
|
|||||
|
Current Ratio
|
2.13
|
1.41
|
1.89
|
6.89
|
6.43
|
0.51
|
|||||
|
Quick Ratio
|
1.96
|
--
|
--
|
7.09
|
6.68
|
0.60
|
|||||
|
Interest Coverage
|
-10.61
|
-8.73
|
-25.44
|
-17.69
|
-15.36
|
-2.40
|
Operating Efficiency Ratios |
TTM | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
140.00
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Asset Turnover
|
0.01
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Receivable days
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Inventory Days
|
--
|
--
|
-386.33
|
-505.06
|
-596.14
|
-13,349.77
|
|||||
|
Payable days
|
--
|
3,772.57
|
810.86
|
370.53
|
147.04
|
18,491.63
|
|||||
|
Cash Conversion Cycle
|
--
|
--
|
--
|
--
|
--
|
--
|